Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Concomitant Administration	Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™
Non-concomitant Administration	Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™

Participant Flow:   Overall Study

	Concomitant Administration	Non-concomitant Administration
STARTED	518	524
COMPLETED	499	494
NOT COMPLETED	19	30
Lost to Follow-up	6	14
Withdrawal by Subject	12	14
Protocol Deviation	0	1
Moved	0	1
Patient Discontinued for Other	1	0

Reporting Groups

	Description
Concomitant Administration	Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™
Non-concomitant Administration	Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™

Baseline Measures

	Concomitant Administration	Non-concomitant Administration	Total
Number of Participants   [units: participants]	518	524	1042
Age   [units: years] Mean ± Standard Deviation	12.5 ± 1.84	12.7 ± 1.90	12.6 ± 1.88
Age, Customized   [units: participants]
9 Years of Age and Under	0	0	0
10 to 17 Years of Age	518	524	1042
Over 17 Years of Age	0	0	0
Gender   [units: participants]
Female	308	340	648
Male	210	184	394
Race/Ethnicity   [units: participants]
Asian	5	7	12
Black	54	74	128
Hispanic American	42	29	71
Indian	1	1	2
Multi-Racial	9	6	15
Native American	1	3	4
White	406	404	810

1.  Primary:

Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)   [ 7 Months ]

2.  Primary:

Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 (7 Months)   [ 7 Months ]

3.  Primary:

Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)   [ 7 Months ]

4.  Primary:

Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 24 mMU/mL) by Week 4 Postdose 3 (7 Months)   [ 7 Months ]

5.  Primary:

Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A One Month Postvaccination (Week 4 Postdose 1) With Menactra™   [ 7 Months ]

6.  Primary:

Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup C One Month Postvaccination (Week 4 Postdose 1) With Menactra™   [ 7 Months ]

7.  Primary:

Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup W-135 One Month Postvaccination (Week 4 Postdose 1) With Menactra™   [ 7 Months ]

8.  Primary:

Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup Y One Month Postvaccination With Menactra™   [ 7 Months ]

9.  Primary:

Number of Subjects Who Achieved Acceptable Levels of Titers (Diphtheria ≥ 0.1 IU/mL) to Diphtheria One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]

10.  Primary:

Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]

11.  Primary:

Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 (7 Months) of GARDASIL™   [ 7 Months ]

12.  Primary:

Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 (7 Months) of GARDASIL™   [ 7 Months ]

13.  Primary:

Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 (7 Months) of GARDASIL™   [ 7 Months ]

14.  Primary:

Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 (7 Months) of GARDASIL™   [ 7 Months ]

15.  Primary:

Geometric Mean Titers (GMTs) for Pertussis Anti-Pertussis Toxin (Anti-PT) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]

16.  Primary:

Geometric Mean Titers (GMTs) for Pertussis Anti-Filamentous Hemagglutinin) (Anti-FHA) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]

17.  Primary:

Geometric Mean Titers (GMTs) for Pertussis Anti Pertactin (Anti-PRN) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]

18.  Primary:

Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™   [ 7 Months ]